Oruka Therapeutics officer proposes $2.34M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. (ORKA) officer Paul Quinlan reported a proposed sale of 24,000 common shares, with an aggregate market value of $2,341,680.00 and an approximate sale date of November 20, 2026. His listed three-month sales history includes 9,000 shares for $706,734.90 on October 20, 2026, and 10,000 shares for $936,418.00 on September 21, 2026, both identified as Rule 10b5-1 sales. It also lists 1,039 shares sold on September 15, 2026, for $99,442.69.
Key Figures
Key Terms
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.